UBS Group Issues Pessimistic Forecast for Kenvue (NYSE:KVUE) Stock Price

Kenvue (NYSE:KVUE) had its price objective lowered by UBS Group from $23.00 to $21.00 in a report published on Friday,Benzinga reports. The firm currently has a neutral rating on the stock.

KVUE has been the topic of a number of other reports. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Barclays reduced their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and increased their price target for the company from $21.00 to $26.00 in a research note on Monday, January 6th. JPMorgan Chase & Co. lifted their price objective on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $23.00.

Kenvue Stock Performance

NYSE KVUE opened at $20.23 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue has a twelve month low of $17.67 and a twelve month high of $24.46. The business has a 50-day moving average price of $21.54 and a 200-day moving average price of $21.97. The firm has a market cap of $38.79 billion, a price-to-earnings ratio of 38.17, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities research analysts predict that Kenvue will post 1.05 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 4.05%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is 154.72%.

Institutional Investors Weigh In On Kenvue

Institutional investors have recently made changes to their positions in the company. Grove Bank & Trust raised its position in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares during the period. Riverview Trust Co bought a new position in shares of Kenvue during the third quarter valued at approximately $30,000. Geneos Wealth Management Inc. purchased a new stake in shares of Kenvue in the fourth quarter worth approximately $29,000. SRS Capital Advisors Inc. lifted its stake in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after acquiring an additional 571 shares during the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in Kenvue during the 3rd quarter valued at $35,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.